UB Paderborn / Katalog / Suche / in CDI

Es ist ein Fehler in der Kommunikation mit einem externen System aufgetreten. Bitte versuchen Sie Ihre letzte Aktion erneut. Sollte der Fehler bestehen bleiben, setzen Sie sich bitte mit dem Informationszentrum der Bibliothek in Verbindung oder versuchen Sie es später erneut.

1 – 25 von 1.195

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Fusobacterium nucleatum persistence and risk of recurrence after preoperative treatment in locally advanced rectal cancer

Annals of oncology, 2020-10, Vol.31 (10), p.1366-1375

2020

Volltextzugriff (PDF)

Plasmatic BRAF-V600E allele fraction as a prognostic factor in metastatic colorectal cancer treated with BRAF combinatorial treatments

Annals of oncology, 2023-06, Vol.34 (6), p.543-552

2023

Volltextzugriff (PDF)

Neisseria gonorrhoeae antimicrobial susceptibility in Barcelona: penA, ponA, mtrR, and porB mutations and NG-MAST sequence types associated with decreased susceptibility to cephalosporins

European journal of clinical microbiology & infectious diseases, 2016-09, Vol.35 (9), p.1549-1556

2016

Volltextzugriff (PDF)

Corrigendum to “Plasmatic BRAF-V600E allele fraction as a prognostic factor in metastatic colorectal cancer treated with BRAF combinatorial treatments”: [Annals of Oncology 34 (2023) 543-552]

Annals of oncology, 2024-10, Vol.35 (10), p.922-922

2024

Volltextzugriff (PDF)

Differences in Neisseria gonorrhoeae population structure and antimicrobial resistance pattern between men who have sex with men and heterosexuals

Epidemiology and infection, 2017-01, Vol.145 (2), p.379-385

2017

Volltextzugriff (PDF)

CES1 genetic variation affects the activation of angiotensin-converting enzyme inhibitors

The pharmacogenomics journal, 2016-06, Vol.16 (3), p.220-230

2016

Volltextzugriff (PDF)

Combination Strategies for Semantic Role Labeling

The Journal of artificial intelligence research, 2007-01, Vol.29, p.105-151

2007

Volltextzugriff (PDF)

Mortality of women with ductal carcinoma in situ of the breast: a population-based study from the Girona province, Spain (1994–2013)

Clinical & translational oncology, 2019-07, Vol.21 (7), p.891-899

2019

Volltextzugriff (PDF)

Carbon cycling in northern peatlands

1, 2009

Volltextzugriff (PDF)

Suposiciones de la "evaluación externa-estímulos económicos" al profesorado universitario: Método de contraste España-México

Revista de la educación superior, 2018-03, Vol.47 (185), p.57-81

2018

Volltextzugriff (PDF)

Corrigendum to "Plasmatic BRAF-V600E allele fraction as a prognostic factor in metastatic colorectal cancer treated with BRAF combinatorial treatments": Annals of Oncology 34 (2023) 543-552

Annals of oncology, 2024-10, Vol.35 (10), p.922

2024

Volltextzugriff (PDF)

125P Circulating tumour DNA (ctDNA) as a prognostic biomarker in patients (pts) with refractory metastatic colorectal cancer (mCRC) receiving TAS102 with or without bevacizumab

Annals of oncology, 2024-06, Vol.35, p.S58-S59

2024

Volltextzugriff (PDF)

PD-12 Characterization of best responder patients to oxaliplatin rechallenge in patients with refractory metastatic colorectal cancer (mCRC)

Annals of oncology, 2022-06, Vol.33, p.S243-S244

2022

Volltextzugriff (PDF)

88P Real-world data of patients (pts) with BRAF V600E-mutated (mt) metastatic colorectal cancer (mCRC) treated with trifluridine/tipiracil (FTD–TPI)

Annals of oncology, 2024-06, Vol.35, p.S43-S43

2024

Volltextzugriff (PDF)

121P Early and easy-to-retrieve predictive biomarkers of resistance to immunotherapy in microsatellite instability (MSI)/mismatch repair deficient (dMMR) metastatic colorectal cancer (mCRC)

Annals of oncology, 2024-06, Vol.35, p.S56-S57

2024

Volltextzugriff (PDF)

P-268 Using 16S rRNA gene sequencing to investigate the composition of Fusobacterium-associated microbiota and its impact on outcome in rectal cancer

Annals of oncology, 2023-06, Vol.34, p.S110-S110

2023

Volltextzugriff (PDF)

626P Mucinous differentiation (MD) as predictor of response in BRAF-V600E mutated metastatic colorectal cancer (mCRC) treated with BRAF inhibitors (BRAFi) combinations

Annals of oncology, 2023-10, Vol.34, p.S447-S447

2023

Volltextzugriff (PDF)

579P Intratumoral fusobacterium as prognostic factor in early stage colorectal cancer: Results of the FUSOMAP study

Annals of oncology, 2024-09, Vol.35, p.S469-S470

2024

Volltextzugriff (PDF)

76P Association of clinicopathological (C-P) features and tumor (tum) immune contexture with dissemination pattern in metastatic colorectal cancer (mCRC)

Annals of oncology, 2024-06, Vol.35, p.S37-S38

2024

Volltextzugriff (PDF)

2314P Quality and safety of research biopsies (RB) in oncology clinical trials

Annals of oncology, 2023-10, Vol.34, p.S1182-S1183

2023

Volltextzugriff (PDF)

374P Influence of sex on safety and efficacy in BRAF-V600E mutated metastatic colorectal cancer (mCRC) treated with encorafenib-cetuximab +/-binimetinib (E-C+/-B)

Annals of oncology, 2022-09, Vol.33, p.S707

2022

Volltextzugriff (PDF)

LBA-3 Integrated analysis of cell-free DNA (cfDNA) BRAF mutant allele fraction (MAF) and whole exome sequencing in BRAFV600E metastatic colorectal cancer (mCRC) treated with BRAF-antiEGFR +/- MEK inhibitors

Annals of oncology, 2021-07, Vol.32, p.S226-S227

2021

Volltextzugriff (PDF)

445P Tumor load surrogates as major prognostic factors in BRAF-V600E mutated (mt) colorectal (CRC) patients treated with BRAF inhibitor+antiEGFR +/- MEK inhibitor

Annals of oncology, 2021-09, Vol.32, p.S556-S556

2021

Volltextzugriff (PDF)

CP-051 Comparing the efficacy of afatinib versus erlotinib or gefitinib in non-small cell lung cancer patients

European journal of hospital pharmacy. Science and practice, 2017-03, Vol.24 (Suppl 1), p.A22-A23

2017

Volltextzugriff (PDF)

CP-026 Renal safety of tenofovir and cobicistat

European journal of hospital pharmacy. Science and practice, 2017-03, Vol.24 (Suppl 1), p.A11-A11

2017

Volltextzugriff (PDF)

1 – 25 von 1.195

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(1.025)
Mit Volltextzugriff
(1.035)

Publikationsform

2 weitere anzeigen...

Weniger anzeigen...

Sprache

3 weitere anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(11)

Menü

Weitere Dienste

Einstellungen

Fusobacterium nucleatum persistence and risk of recurrence after preoperative treatment in locally advanced rectal cancer

Plasmatic BRAF-V600E allele fraction as a prognostic factor in metastatic colorectal cancer treated with BRAF combinatorial treatments

Neisseria gonorrhoeae antimicrobial susceptibility in Barcelona: penA, ponA, mtrR, and porB mutations and NG-MAST sequence types associated with decreased susceptibility to cephalosporins

Corrigendum to “Plasmatic BRAF-V600E allele fraction as a prognostic factor in metastatic colorectal cancer treated with BRAF combinatorial treatments”: [Annals of Oncology 34 (2023) 543-552]

Differences in Neisseria gonorrhoeae population structure and antimicrobial resistance pattern between men who have sex with men and heterosexuals

CES1 genetic variation affects the activation of angiotensin-converting enzyme inhibitors

Combination Strategies for Semantic Role Labeling

Mortality of women with ductal carcinoma in situ of the breast: a population-based study from the Girona province, Spain (1994–2013)

Carbon cycling in northern peatlands

Suposiciones de la "evaluación externa-estímulos económicos" al profesorado universitario: Método de contraste España-México

Corrigendum to "Plasmatic BRAF-V600E allele fraction as a prognostic factor in metastatic colorectal cancer treated with BRAF combinatorial treatments": Annals of Oncology 34 (2023) 543-552

125P Circulating tumour DNA (ctDNA) as a prognostic biomarker in patients (pts) with refractory metastatic colorectal cancer (mCRC) receiving TAS102 with or without bevacizumab

PD-12 Characterization of best responder patients to oxaliplatin rechallenge in patients with refractory metastatic colorectal cancer (mCRC)

88P Real-world data of patients (pts) with BRAF V600E-mutated (mt) metastatic colorectal cancer (mCRC) treated with trifluridine/tipiracil (FTD–TPI)

121P Early and easy-to-retrieve predictive biomarkers of resistance to immunotherapy in microsatellite instability (MSI)/mismatch repair deficient (dMMR) metastatic colorectal cancer (mCRC)

P-268 Using 16S rRNA gene sequencing to investigate the composition of Fusobacterium-associated microbiota and its impact on outcome in rectal cancer

626P Mucinous differentiation (MD) as predictor of response in BRAF-V600E mutated metastatic colorectal cancer (mCRC) treated with BRAF inhibitors (BRAFi) combinations

579P Intratumoral fusobacterium as prognostic factor in early stage colorectal cancer: Results of the FUSOMAP study

76P Association of clinicopathological (C-P) features and tumor (tum) immune contexture with dissemination pattern in metastatic colorectal cancer (mCRC)

2314P Quality and safety of research biopsies (RB) in oncology clinical trials

374P Influence of sex on safety and efficacy in BRAF-V600E mutated metastatic colorectal cancer (mCRC) treated with encorafenib-cetuximab +/-binimetinib (E-C+/-B)

LBA-3 Integrated analysis of cell-free DNA (cfDNA) BRAF mutant allele fraction (MAF) and whole exome sequencing in BRAFV600E metastatic colorectal cancer (mCRC) treated with BRAF-antiEGFR +/- MEK inhibitors

445P Tumor load surrogates as major prognostic factors in BRAF-V600E mutated (mt) colorectal (CRC) patients treated with BRAF inhibitor+antiEGFR +/- MEK inhibitor

CP-051 Comparing the efficacy of afatinib versus erlotinib or gefitinib in non-small cell lung cancer patients

CP-026 Renal safety of tenofovir and cobicistat

Suchergebnisse filtern